At last check-in after-hours trading, shares of Biocept Inc. (BIOC) were up 6.30% at $2.70. BIOC’s stock closed the last session at $2.54, decreasing -1.17% or -$0.03. Shares of the company fluctuated between $2.50 and $2.60 throughout the day. The number of shares exchanged was 86006.0, less than the company’s 50-day daily volume of 0.19 million and lower than its Year to date volume of 0.17 million.
In the past 12 months, Biocept Inc. stock has advanced -64.07%, and in the last one week, the stock has moved down -4.51%. For the last six months, the stock has lost a total of -28.25%, and over the last three months, the stock has decreased by -34.70%. The stock has returned -29.83% so far this year. Additionally, the stock is trading at a price-to-earnings ratio of 7.49. BIOC stock surged after-hours following the appointment of new leaders.
Who has been designated by BIOC?
Biocept Inc. (BIOC) creates and markets atomic symptomatic measures that give doctors clinically significant data to support the analysis, therapy, and observing of patients with the disease. Notwithstanding its wide arrangement of blood-based fluid biopsy tests, BIOC has fostered the CNSide cerebrospinal liquid measure, intended to analyze malignant growth that has metastasized to the focal sensory system. BIOC likewise is utilizing its atomic symptomatic capacities to offer cross-country RT-PCR-based COVID-19 testing and administrations to help general wellbeing endeavors during this exceptional pandemic.
Biocept Inc. (BIOC) today declared the appointment of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall.
BIOC additionally designated Antonino Morales as Interim Chief Financial Officer, to succeed Timothy C. Kennedy.
Biocept additionally named M. Faye Wilson as Lead Independent Director of the organization’s Board of Directors. Mr. Riccitelli remains Chair of the Board.
The new individuals are venturing into their between-time jobs when BIOC is satisfying a particularly significant mission for its present COVID-19 testing clients.
Their initiative will intend to harm growth patients as BIOC seeks after the clinical approval of the CNSide examine in distinguishing metastatic disease starting from every single strong cancer.
Previous appointment:
Biocept Inc. (BIOC) has as of late designated Darrell Taylor as Senior Vice President, General Counsel, and Chief Compliance Officer. With over 30 years of medical care insight, Taylor will lead fundamental parts of lawful, consistence, and security endeavors, and will answer to BIOC President and CEO.
